drugset / Trial / NCT00902824
Safety and Immunogenicity of TBC-M4, a MVA HIV Vaccine Alone or in a Prime-Boost Regimen With ADVAX DNA HIV Vaccine
RandomizedParallel-groupQuadruple-blindPrevention
Summary
This trial will study a prime-boost vaccine approach designed mainly to induce cell-mediated immune (CTL) responses.
Timeline
- Start
- 2008-11
- Primary completion
- 2010-04
- Completion
- 2010-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | ADVAX | Vaccine | 4 mg | Other |
| Comparator | TBC-M4 | Vaccine | 5e+07 unknown | Intramuscular |